“Save the Veins” Vein Sparing for Patients with Renal Dysfunction
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Blood Collection
Blood Collection (Note: Navigation around this large pdf document is best accomplished using the bookmarks function.) 355.1 Preface Blood collection (venipuncture, phlebotomy) is a common and important specimen collection procedure in the conduct of research. In many protocols, multiple blood draws are an important part of collecting and analyzing data. The Emory University Institutional Animal Care and Use Committee (IACUC) developed a policy to best enable blood collection while minimizing the potential for pain, unnecessary stress, distress or untoward effect in research animals. These are articulated by way of this general overview supplemented by companion documents appropriate to certain species. The species-specific sections differentiate from the general standards in being more precise, and sometimes more adaptable, in considering the frequency and total number of blood collection events; maximum collectable volumes allowed based upon specific physiology; detailing allowable routes particular to each species; differentiating between terminal and survival circumstances; disclosing requirements for anesthesia or restraint; scientific qualifiers and addressing conditionally permissible methods or settings germane to a species. This list is not exhaustive and persons requiring information regarding the supplies and equipment needed, specifics of restraint or anesthesia, requirements for ancillary care, habituation requirements, application to study in the field and other information are encouraged to contact the Training Coordinators for their specific site. o DAR Training Request: http://www.dar.emory.edu/forms/training_wrkshp.php o Yerkes National Primate Research Center Training: Jennifer McMillan, [email protected], 404-712-9217 While it only takes about 24 hours for the lost fluid volume of blood to be restored, it takes longer to regeneratively replenish erythrocytes, platelets and other circulating factors. -
Interaction Between Renal Replacement Therapy And
rren Cu t R y: es Romano, Surgery Curr Res 2014, 4:1 r e e a g r r c u h DOI: 10.4172/2161-1076.1000154 S Surgery: Current Research ISSN: 2161-1076 Review Article Open Access Interaction between Renal Replacement Therapy and Extracorporeal Membrane Oxygenation Support Thiago Gomes Romano* Assistant Teaching Professor for the Discipline of Nephrology, ABC Medical School Medical Intensivist at Hospital, Sírio-Libanês, Brazil Abstract Extracorporeal Membrane Oxygenation (ECMO) is one of the designations used for extracorporeal circuits capable of oxygenation, carbon dioxide removal and, eventually, circulatory support. Acute respiratory distress syndrome with severe hypoxemia or acidemia with high carbon dioxide levels in a scenario of low pulmonary tidal volume is its mainly indication. Acute Kidney Injury (AKI) and its complications such as volume overload and azotemia are common in this situation; some epidemiological studies have shown that around 78% of the patients demanding ECMO therapy develop AKI. Therefore, renal replacement therapy is required in about 50% of those cases. This papers aims to explain the concept of the ECMO circuit and the ways continuous renal replacement therapy (CRRT) can be instituted in critical ill patients who need ECMO. Keywords: ECMO; Renal replacement therapy; Dialysis internal jugular or femoral vein with the return placed in the femoral artery. Additionally, a jugular-carotid cannulation is one option despite Introduction the potential for neurological injury. In cases exclusively intended for Extracorporeal Membrane Oxygenation (ECMO) is one of the ventilatory support [venovenous (VV) ECMO], cannulation can be designations used for extracorporeal circuits capable of oxygenation, placed femoro-jugular, jugular-femoral or femoral-femoral depending carbon dioxide (CO ) removal and, eventually, circulatory support. -
The Incidence of Microemboli to the Brain Is Less with Endarterectomy Than with Percutaneous Revascularization with Distal filters Or flow Reversal
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector From the Southern Association for Vascular Surgery The incidence of microemboli to the brain is less with endarterectomy than with percutaneous revascularization with distal filters or flow reversal Naren Gupta, MD, PhD,a Matthew A. Corriere, MD, MS,a,c Thomas F. Dodson, MD,a Elliot L. Chaikof, MD, PhD,a Robert J. Beaulieu, BS,b James G. Reeves, MD,a Atef A. Salam, MD,a and Karthikeshwar Kasirajan, MD,a Atlanta, Ga Background: Current data suggest microembolization to the brain may result in long-term cognitive dysfunction despite the absence of immediate clinically obvious cerebrovascular events. We reviewed a series of patients treated electively with carotid endarterectomy (CEA), carotid artery stenting (CAS) with distal filters, and carotid stenting with flow reversal (FRS) monitored continuously with transcranial Doppler scan (TCD) during the procedure to detect microembolization rates. Methods: TCD insonation of the M1 segment of the middle cerebral artery was conducted during 42 procedures (15 CEA, 20 CAS, and 7 FRS) in 41 patients seen at an academic center. One patient had staged bilateral CEA. Ipsilateral microembolic signals (MESs) were divided into three phases: preprotection phase (until internal carotid artery [ICA] cross-shunted or clamped if no shunt was used, filter deployed, or flow reversal established), protection phase (until clamp/shunt was removed, filter removed, or antegrade flow re-established), and postprotection phase (after clamp/ shunt was removed, filter removed, or antegrade flow re-established). Descriptive statistics are reported as mean ؎ SE for continuous variables and N (%) for categorical variables. -
Digital Vein Mapping Guiding Laser and Injection Sclerotherapy to Treat Telangiectasias and Feeder Veins: Report of 140 Cases
ARTÍCULO ORIGINAL Digital Vein Mapping Guiding Laser and Injection sclerotherapy to treat telangiectasias and Feeder Veins: Report of 140 Cases. Authors: Roberto Kasuo Miyake, MD, PhD / Rodrigo Kikuchi, MD / Flavio Henrique Duarte, MD / John Davidson, MD / Hiroshi Miyake, MD, PhD Institution: Clinica Miyake, Sao Paulo, Brazil E-Mail autor: [email protected] Fecha recepción artículo: 23/11/2008 - Fecha aceptación artículo: Marzo 2009 Abstract Resumen Background and Objective: Telangiectasias Antecedentes y Objetivo: la ineficiencia en el treatment inefficiency may occur due to tratamiento de las telangiectasias puede deber- invisible feeder veins. These veins can be made se a las venas nutricias no visibles. Estas venas discernible by use of a digital vein detection pueden hacerse perceptibles mediante el uso de device (V-V). This study evaluates a method un dispositivo digital de detección (VV). Este to treat vascular lesions by combining 1064nm estudio evalúa un método para el tratamiento laser, injection sclerotherapy, a skin cooling de lesiones vasculares mediante la combinación device (CLaCS) and the V-V. de láser de 1064nm, la escleroterapia por inyec- Materials and Methods: Patients were treated ción y un dispositivo de enfriamiento de la piel with laser and sclerotherapy, both applied (CLACS, Cryo-Laser y Cryo-Sclerotherapy)) y under cooling. V-V was used to visualize hidden el VV (The VeinViewer™). feeder veins. Material y Métodos: Los pacientes fueron trata- Results: A total of 140 patients underwent dos con láser y la escleroterapia, ambos aplicados CLaCS. In 121 patients (86%) satisfactory bajo enfriamiento con (CLaCS). El dispositivo cosmetic results were obtained avoiding digital V-V se utiliza para visualizar las venas phlebectomy. -
Research Article Endothelial Dysfunction of Patients with Peripheral Arterial Disease Measured by Peripheral Arterial Tonometry
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation International Journal of Vascular Medicine Volume 2016, Article ID 3805380, 6 pages http://dx.doi.org/10.1155/2016/3805380 Research Article Endothelial Dysfunction of Patients with Peripheral Arterial Disease Measured by Peripheral Arterial Tonometry Kimihiro Igari, Toshifumi Kudo, Takahiro Toyofuku, and Yoshinori Inoue Division of Vascular and Endovascular Surgery, Department of Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan Correspondence should be addressed to Kimihiro Igari; [email protected] Received 16 July 2016; Revised 17 September 2016; Accepted 27 September 2016 Academic Editor: Thomas Schmitz-Rixen Copyright © 2016 Kimihiro Igari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Endothelial dysfunction plays a key role in atherosclerotic disease. Several methods have been reported to be useful for evaluating the endothelial dysfunction, and we investigated the endothelial dysfunction in patients with peripheral arterial disease (PAD) using peripheral arterial tonometry (PAT) test in this study. Furthermore, we examined the factors significantly correlated with PAT test. Methods. We performed PAT tests in 67 patients with PAD. In addition, we recorded the patients’ demographics, including comorbidities, and hemodynamical status, such as ankle brachial pressure index (ABI). Results. In a univariate analysis, the ABI value ( = 0.271, = 0.029) and a history of cerebrovascular disease ( = 0.208, = 0.143) were found to significantly correlatewithPATtest,whichcalculatedthereactivehyperemiaindex(RHI).Inamultivariateanalysis,onlytheABIvalue significantly and independently correlated with RHI ( = 0.254, = 0.041). -
Overview of Complications of Hemodialysis Access
Update on Hemodialysis Access Raymond J. Holmes, MD April 4th, 2019 Presenter Disclosure Information Raymond J. Holmes, MD The Cardiovascular Care Group FINANCIAL DISCLOSURE: Nothing to disclose UNLABELED/UNAPPROVED USES DISCLOSURE: No unlabeled and or unapproved off-label use of products or devices will be discussed in this presentation Update on Hemodialysis Access Surgery • Overview: K-DOQI and Fistula First • Strategy for sequential access placement • AV fistula, AV graft, basilic vein transposition, HeRO device • Endovascular Intervention • Complications In the Beginning… Belding Scribner 1921-2003 Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula Michael J. Brescia, M.D., James E. Cimino, M.D., Kenneth Appel, M.D. and Baruch J. Hurwich, M.D. NEJM 275:1089-1092, 1966. James E. Cimino (1928-2010) What is the best access for hemodialysis? • 53 years after initial description of the AV fistula, it still remains the best access for hemodialysis Michael J. Brescia, M.D., James E. Cimino, M.D., Kenneth Appel, M.D. and Baruch J. Hurwich, M.D. NEJM 275:1089-1092, 1966. DOQI Guidelines • Developed by National Kidney Foundation. (www.kidney.org) • Common sense, common practice • Some “evidence” based; some opinion based. • Careful disclaimers not to be “standard of care” – However, widely adapted as “standard of care”. Guidelines on topics for management of patients with chronic kidney disease including vascular access •Clinical Practice Guidelines for Vascular Access, Update 2006 •Guideline 1. Patient Preparation for Permanent Hemodialysis Access •Guideline 2. Selection and Placement of Hemodialysis Access •Guideline 3. Cannulationof Fistulae and Grafts and Accession of Hemodialysis Catheters and Port Catheter Systems •Guideline 4. -
Hemodialysis
The Ohio State University Veterinary Medical Center Hemodialysis What is hemodialysis? Hemodialysis is a method of blood purification that This is most commonly performed in the acute setting removes blood from the body through a catheter (acute kidney injury) for animals but may also be elected and filters it through a dialyzer (artificial kidney). for patients with chronic kidney dysfunction. Hemodialysis is used to purify the blood by eliminating While acute kidney injury is the most common reason toxic metabolites, balancing electrolytes, and removing for performing hemodialysis, it can also be used to treat excess water that builds up when the kidneys are acute intoxications to enhance elimination of a toxin. unable to excrete it. Indications for Hemodialysis Acute Kidney Injury This is the most common indication for hemodialysis. 10-14 days of hospitalization and treatment. With acute This procedure should be considered when clinical kidney injury, the kidneys typically start to regain some uremia, hyperkalemia, acid/base disturbances, and function within this time period, but a lack of response fluid overload cannot be managed with conventional does not mean the kidneys will never recover. medical therapy. The best time to start hemodialysis There are instances when it may take up to four weeks is still unknown (even in human medicine), but starting to become dialysis independent. Patients are generally treatment sooner means fewer side effects from uremia. transitioned after the 10-14 days to outpatient treatments Thus, hemodialysis should be considered sooner rather to continue to provide time for the kidneys to recover. than later. Outpatient treatments allow families to play an active When hemodialysis is performed, pet owners should role in facilitating recovery. -
UNDERSTANDING YOUR HEMODIALYSIS OPTIONS Hemodialysis Is a Treatment for Access People Whose Kidneys Are No Longer Involves Working
UNDERSTANDINGUnderstanding YOUR HEMODIALYSISYour OPTIONS Hemodialysis Access Options This educational activity is supported by a donation by Amgen, Inc UNDERSTANDING YOUR HEMODIALYSIS OPTIONS Hemodialysis is a treatment for access people whose kidneys are no longer involves working. The treatment removes making a waste products and fluid from the connection blood using an artificial kidney between an machine. It is the most common artery and a treatment for people who have end- vein under stage renal disease (ESRD), or whose the skin. A kidneys no longer work. surgeon will make There are four types of hemodialysis your fistula treatment options. AAKP created this or graft brochure to explain each of your by sewing treatment options, and to show you one of your the pros and cons of each option. arteries to Mayo Clinic Foundation for one of your Education and Research veins. It’s CREATING AN ACCESS a simple medical procedure. Your surgeon Before you begin hemodialysis chooses which artery and vein to treatment, a surgeon must create connect depending on how fast your an access for the machine. Don’t be blood flows through the artery and afraid. Access for the machine will vein. be at a place on your body close to a vein and artery. It allows access A catheter is the other type of to your blood stream. Blood goes access. A catheter is a thin, flexible from your body through the access tube that can be put through a small and to the dialysis machine. Once hole in your body. A surgeon inserts inside the artificial kidney machine, the catheter through your skin into the machine cleans the blood and a large vein in the neck, chest or returns the clean blood back to groin. -
Ultrafiltration I Hemodialysis During Cardiopulmonary Bypass: a Case Report
THE jOURNAL OF EXTRA-CORPOREAL TECHNOLOGY Case Report Ultrafiltration I Hemodialysis During Cardiopulmonary Bypass: A Case Report Scott D. Niles, BA, Robin G. Sutton, MS, CCP, Richard P. Embrey, MD University of Iowa Hospitals and Clinics, Iowa City, Iowa Keywords: cardiopulmonary bypass; hemodialysis, concurrent; technique; ultrafiltration. ABSTRACT Patient demographics for elective cardiovascular surgery have shifted toward older patients with more profound disease states. Cardiopulmonary bypass is complicated when the patient presents with end stage renal disease. Hemodialysis during cardiopulmonary bypass has been successfully employed to reduce the postoperative sequelae associated with cardiopulmo nary bypass. A patient with end stage renal disease who presented for coronary artery bypass grafting serves as the subject of this case report. Utilizing a modified technique previously described by Wiggins and Dearing, we describe successful intraoperative use of hemodialysis during cardiopulmonary bypass. Our experience suggests that hemodialysis during cardiopulmo nary bypass is an effective alternative to ultrafiltration and may prolong the time interval for resumption of postoperative dialysis regimens. Address correspondence to: Scott D. Niles University of Iowa Hospitals and Clinics Perfusion Technology Program Department of Surgery Division of Cardiothoracic Surgery 1600 JCP Iowa City, lA 52242 104 Volume 27, Number 2, June 1995 THE jOURNAL OF EXTRA-CORPOREAL TECHNOLOGY INTRODUCTION helping to resolve elevated BUN and creatinine levels. A hemodialysis circuit was constructed in parallel with the Population demographics in patients undergoing elective cardiopulmonary bypass circuit (Figure 1). A purge port on top cardiovascular surgery have undergone dramatic changes over of the arterial filter served as the blood source for an ultrafiltration the past twenty years, With a trend toward older patients with hemoconcentrator which then emptied into a venous reservoir bag. -
Diagnostic Blood Loss from Phlebotomy and Hospital-Acquired Anemia During Acute Myocardial Infarction
ORIGINAL INVESTIGATION ONLINE FIRST |LESS IS MORE Diagnostic Blood Loss From Phlebotomy and Hospital-Acquired Anemia During Acute Myocardial Infarction Adam C. Salisbury, MD, MSc; Kimberly J. Reid, MS; Karen P. Alexander, MD; Frederick A. Masoudi, MD, MSPH; Sue-Min Lai, PhD, MS, MBA; Paul S. Chan, MD, MSc; Richard G. Bach, MD; Tracy Y. Wang, MD, MHS, MSc; John A. Spertus, MD, MPH; Mikhail Kosiborod, MD Background: Hospital-acquired anemia (HAA) during Results: Moderate to severe HAA developed in 3551 pa- acute myocardial infarction (AMI) is associated with tients(20%).Themean(SD)phlebotomyvolumewashigher higher mortality and worse health status and often de- in patients with HAA (173.8 [139.3] mL) vs those without velops in the absence of recognized bleeding. The ex- HAA (83.5 [52.0 mL]; PϽ.001). There was significant varia- tent to which diagnostic phlebotomy, a modifiable pro- tion in the mean diagnostic blood loss across hospitals (mod- cess of care, contributes to HAA is unknown. erate to severe HAA: range, 119.1-246.0 mL; mild HAA or no HAA: 53.0-110.1 mL). For every 50 mL of blood drawn, the risk of moderate to severe HAA increased by 18% (rela- Methods: We studied 17 676 patients with AMI from tiverisk[RR],1.18;95%confidenceinterval[CI],1.13-1.22), 57 US hospitals included in a contemporary AMI data- which was only modestly attenuated after multivariable ad- base from January 1, 2000, through December 31, 2008, justment (RR, 1.15; 95% CI, 1.12-1.18). who were not anemic at admission but developed mod- erate to severe HAA (in which the hemoglobin level de- Conclusions: Blood loss from greater use of phle- Ͻ clined from normal to 11 g/dL), a degree of HAA that botomy is independently associated with the develop- has been shown to be prognostically important. -
Preparing for Vascular Access Surgery
Form: D-5134 Preparing for Vascular Access Surgery Information for patients and families Read this booklet to learn: • why you need vascular access for hemodialysis • what an AV graft and an AV fistula is • what to expect with this procedure • who to call if you have any questions Check in at: Toronto General Hospital Surgical Admission Unit (SAU), Peter Munk Building – 2nd Floor Date and time of my surgery: Date: Time: *Remember: You need to arrive at the hospital 2 hours before surgery Why do I need vascular access surgery? If you need hemodialysis, you need a vein that is easy to find and use. Vascular access surgery makes an access site for the hemodialysis. This is called an arteriovenous (AV) access. An AV access connects your artery directly to your vein. If this is not possible, a soft plastic tube will be used to connect your artery and vein. How does my AV access work during hemodialysis? Before hemodialysis (or dialysis), your nurse will put 2 needles into your AV access. One needle takes the blood from your body to the artificial kidney (dialyzer). This cleans your blood. The second needle returns the clean blood back to you. Only a small amount of blood (about 1 cup) is removed from your body at one time. At the end, your nurse removes both needles and puts bandages where the needles were put in. You can take the bandages off the next day. 2 Your AV access will usually be in your forearm or upper arm. There are 2 types of AV access your surgeon could give you. -
Uremic Toxins and Blood Purification: a Review of Current Evidence and Future Perspectives
toxins Review Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives Stefania Magnani * and Mauro Atti Aferetica S.r.l, Via Spartaco 10, 40138 Bologna (BO), Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0535-640261 Abstract: Accumulation of uremic toxins represents one of the major contributors to the rapid progression of chronic kidney disease (CKD), especially in patients with end-stage renal disease that are undergoing dialysis treatment. In particular, protein-bound uremic toxins (PBUTs) seem to have an important key pathophysiologic role in CKD, inducing various cardiovascular complications. The removal of uremic toxins from the blood with dialytic techniques represents a proved approach to limit the CKD-related complications. However, conventional dialysis mainly focuses on the removal of water-soluble compounds of low and middle molecular weight, whereas PBTUs are strongly protein-bound, thus not efficiently eliminated. Therefore, over the years, dialysis techniques have been adapted by improving membranes structures or using combined strategies to maximize PBTUs removal and eventually prevent CKD-related complications. Recent findings showed that adsorption-based extracorporeal techniques, in addition to conventional dialysis treatment, may effectively adsorb a significant amount of PBTUs during the course of the sessions. This review is focused on the analysis of the current state of the art for blood purification strategies in order to highlight their potentialities and limits and identify the most feasible solution to improve toxins removal effectiveness, exploring possible future strategies and applications, such as the study of a synergic approach by reducing PBTUs production and increasing their blood clearance.